Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map

Derm News: 2007.23(10)

Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and SÚzary syndrome

Journal of the American Academy of Dermatology, 56(4):580-583
Christiane Querfeld, Steven T. Rosen, Joan Guitart, Alfred Rademaker, Francine Foss, Rohit Gupta, Timothy M. Kuzel

We conducted a phase II trial to evaluate the efficacy and toxicity of subcutaneous injections of recombinant interleukin (IL)-2 in 22 heavily pretreated patients with advanced cutaneous T-cell lymphoma. We observed modest response rates (18%) with a reasonable toxicity profile. The role of IL-2 in vivo for expansion of cytotoxic CD8+ T cells, CD4+ T cells, regulatory CD25+ T cells, or a combination of these has not been elucidated. There was no evidence of expansion of CD8+ T cells in peripheral blood of patients during treatment. Immunophenotypic analysis revealed an increase of CD25+ cells in CD3+ and CD4+ populations after treatment in a subset of patients possibly reflecting activation of reactive helper T cells, proliferation of neoplastic T cells, or proliferation of T-regulatory cells. In summary, at this dose and schedule recombinant IL-2 is largely ineffective as therapy in patients with advanced cutaneous T-cell lymphoma. Whether IL-2 has the potential to suppress antitumor activity by stimulation of regulatory T cells needs to be clarified.

    Back to Current Volume:   Dermatology News 2007.23

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter© and its founding editor Dr. Stuart Maddin.